VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.
| Fireside Chat Presentation Details: | |
| Date: | Tuesday, March 4, 2025 |
| Time: | 10:30-11:00 AM Eastern Time |
| Webcast: | Register here |
| Presenters: | Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer |
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$39.21 |
| Daily Change: | 0.38 0.98 |
| Daily Volume: | 627,415 |
| Market Cap: | US$3.020B |
August 11, 2025 June 03, 2025 May 14, 2025 May 12, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
